

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Wadih ARAP *et al.*

Serial No.: 10/530,168

Filed: April 4, 2005


For: COMPOSITIONS AND METHODS OF
USE OF TARGETING PEPTIDES FOR
DIAGNOSIS AND THERAPY OF
HUMAN CANCER

Group Art Unit: 1642

Examiner: Christopher H. YAEN

Atty. Dkt. No.: UTSC:857US

Confirmation No.: 5612

CERTIFICATE OF ELECTRONIC TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
February 23, 2007 Date	 David L. Parker

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:857US.

This application is related by inventorship and subject matter to co-pending U.S. Application No. 10/363,208, filed March 7, 2003.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 23, 2007

Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket No. UTSC:857US	Serial No. 10/530,168
	Applicant Wadih Arap, et al.	
	Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2003/0113320	6/19/03	Ruoslahti <i>et al.</i>	424	143.1	10/03/02
	A2	2001/0046498	11/29/01	Rouslahti <i>et al.</i>	424	178.1	1/17/01
	A3	4,472,509	9/18/84	Gansow and Strand	436	548	6/07/82
	A4	4,912,040	3/27/90	Kaufman and Dorner	435	69.6	2/03/87
	A5	4,931,053	06/05/90	L'Esperance, Jr.	606	2	01/27/88
	A6	5,021,236	6/04/91	Gries <i>et al.</i>	424	9	3/02/87
	A7	5,081,034	1/14/92	Bevilasqua <i>et al.</i>	435	252.33	11/14/88
	A8	5,098,833	03/24/92	Lasky <i>et al.</i>	435	69.1	2/23/89
	A9	5,188,964	2/23/93	McGuire <i>et al.</i>	436	64	4/12/90
	A10	5,196,523	3/23/93	Lee	536	23.5	5/19/89
	A11	5,206,347	4/27/93	Ruoslahti <i>et al.</i>	530	413	7/13/90
	A12	5,216,131	6/01/93	Lasky <i>et al.</i>	435	69.1	2/23/89
	A13	5,223,409	6/29/93	Ladner <i>et al.</i>	435	69.7	3/01/91
	A14	5,225,538	7/06/93	Capon <i>et al.</i>	530	387.3	12/16/91
	A15	5,259,380	11/09/93	Mendes <i>et al.</i>	607	115	11/15/90
	A16	5,270,163	12/14/93	Gold <i>et al.</i>	435	6	8/17/92
	A17	5,288,846	2/22/94	Quertermous <i>et al.</i>	435	172.3	8/03/92
	A18	5,304,640	4/19/94	Asky <i>et al.</i>	536	23.5	2/13/92
	A19	5,415,874	5/16/95	Bender <i>et al.</i>	424	520	10/31/89
	A20	5,428,130	6/27/95	Capon <i>et al.</i>	530	350	12/08/92
	A21	5,453,362	9/26/95	Lamarco <i>et al.</i>	435	69.1	4/12/93
	A22	5,463,026	10/31/95	Nakamura and Sato	530	387.3	2/24/94
	A23	5,464,436	11/07/95	Smith	607	89	04/28/94

25716066.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	5,492,807	2/20/96	Santi	435	5	11/19/93
	A25	5,506,126	4/09/96	Seed <i>et al.</i>	435	172.3	1/18/93
	A26	5,536,814	7/16/96	Ruoslahti <i>et al.</i>	530	329	3/11/94
	A27	5,585,277	12/17/96	Bowie <i>et al.</i>	436	518	03/21/95
	A28	5,622,699	4/22/97	Ruoslahti <i>et al.</i>	424	93.6	9/11/95
	A29	5,670,312	9/23/97	Santi	435	5	11/17/95
	A30	5,688,692	11/18/97	Jat <i>et al.</i>	435	354	2/11/93
	A31	5,688,935	11/18/97	Stephens <i>et al.</i>	536	23.1	5/03/95
	A32	5,705,610	1/06/98	Zuckerman <i>et al.</i>	530	338	10/01/93
	A33	5,750,344	5/12/98	Doyle	435	6	10/04/95
	A34	5,840,841	11/24/98	Zuckerman <i>et al.</i>	530	338	5/08/97
	A35	5,866,759	2/02/99	Jat <i>et al.</i>	800	3	7/02/97
	A36	5,902,598	5/11/99	Chen and Ashton	424	423	8/28/97
	A37	5,955,572	9/21/99	Ruoslahti and Pasqualini	530	317	5/14/98
	A38	6,057,098	05/02/00	Buechler <i>et al.</i>	435	6	04/04/97
	A39	6,068,829	5/30/00	Ruoslahti and Pasqualini	242	9.1	6/23/97
	A40	6,093,800	7/25/00	Reiter <i>et al.</i>	530	350	9/5/97
	A41	6,174,861	1/16/01	O'Reilly and Folkman	514	12	7/07/99
	A42	6,184,973	02/06/01	Baer <i>et al.</i>	356	36	04/10/98
	A43	6,215,550	04/10/01	Baer <i>et al.</i>	356	36	07/23/98
	A44	6,232,440	5/15/01	Hillman <i>et al.</i>	530	350	4/20/99
	A45	6,261,789	7/17/01	Reiter <i>et al.</i>	435	7.23	2/17/99
	A46	6,271,196	08/07/01	O'Brien	514	2	03/05/96

25716066.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A47	6,350,855	2/26/02	Tobin	530	350	9/15/97
	A48	6,372,720	4/16/02	Longmuir <i>et al.</i>	514	44	2/5/98
	A49	6,399,384	6/04/02	Jat	435	456	9/15/00
	A50	6,458,381	10/01/02	Sourovov and Jung	424	450	2/12/97
	A51	6,528,281	3/04/03	Tobin	435	69.1	6/14/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 99/47554	9/23/99	WIPO	English
	B2	WO 02/020723	3/14/02	WIPO	English
	B3	WO 02/20822	3/14/02	WIPO	English
	B4	WO 03/022991	3/20/03	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Arap <i>et al.</i> , "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <i>Science</i> , 279:377-380, 1998.
	C2	Arap <i>et al.</i> , "Chemotherapy targeted to tumor vasculature," <i>Curr. Opin. Oncol.</i> , 10:560-565, 1998.
	C3	Arap <i>et al.</i> , "Steps toward mapping the human vasculature by phage display." <i>Nature Med.</i> , 8:121-127, 2002.
	C4	Barrow and Soothill, "Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential," <i>Trends Microbiol.</i> , 5:268-271, 1997.
	C5	Bergelson <i>et al.</i> , "Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5," <i>Science</i> , 275:1320-1323, 1997.

25716066.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Brawn <i>et al.</i> , "Prostatic Acid Phosphatase Levels (Enzymatic Method) From Completely Sectioned, Clinically Benign, Whole Prostates," <i>The Prostate</i> , 28:295-299, 1996.
	C7	Burg <i>et al.</i> , "NG2 Proteoglycan-binding Peptides Target Tumor Neovasculature," <i>Cancer Res</i> , 59:2869-2874, 1999.
	C8	Campbell <i>et al.</i> , "Increased Expression of the Interleukin-11 Receptor and Evidence of STAT3 Activation in Prostate Carcinoma." <i>Am. J. Pathol.</i> , 158:25-32, 2001.
	C9	Chen <i>et al.</i> , "Thapsigargin-induced grp78 expression is mediated by the increase of cytosolic free calcium in 9L rat brain tumor cells," <i>J. Cell. Biochem.</i> , 78:404-416, 2000.
	C10	Choongkittaworn <i>et al.</i> , "Expression of prohibitin in rat seminiferous epithelium," <i>Biol. Reprod.</i> , 49(2):300-310, 1993.
	C11	Curnis <i>et al.</i> , "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)," <i>Nat Biotechnol.</i> , (11):1185-90, 2000.
	C12	Database NCBI on STN, Accession Number G69514, Klenk <i>et al.</i> , "The Complete Genome Sequence of the Hyperthermophilic, Sulphate-reducing Archaeon <i>Archaeoglobus Fulgidus</i> ," <i>Nature</i> , 390:364-370, 1997.
	C13	Database NCBI on STN, Accession Number T21276, Matthews <i>et al.</i> , "Direct Submission," 1999.
	C14	Delpino <i>et al.</i> , "Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin," <i>Mol. Membr. Biol.</i> , 15(1):21-26, 1998.
	C15	Ellerby <i>et al.</i> , "Anti- cancer activity of targeted pro-apoptotic peptides," <i>Nature Med.</i> , 5:1032-1038, 1999.
	C16	Giannakouros <i>et al.</i> , "Post-translational Processing of <i>Schizosaccharomyces pombe</i> YPT5 Protein: In Vitro and In Vivo Analysis of Processing Mutants," <i>Journal of Biological Chemistry</i> , 268:24467-24474, 1993.
	C17	Grifman <i>et al.</i> , "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids," <i>Mol. Ther.</i> , 3(6):964-975, 2001.
	C18	Harrington <i>et al.</i> , "Gene Therapy for prostate cancer: current status and future prospects," <i>J. Urol.</i> , 166:1220-1233, 2001.

25716066.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents See Page 1-3	Foreign Patent Documents See Page 3	Other Art See Page 3-7	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Hong <i>et al.</i> , "Adenovirus type 5 fiber knob binds to MHC class I alpha-2 domain at the surface of human epithelial and B lymphoblastoid cells," <i>EMBO J.</i> , 16:2294-2306, 1997.
	C20	Huang <i>et al.</i> , "Comparison of Prostate Secretory Protein With Prostate Specific Antigen and Prostatic Acid Phosphatase as a Serum Biomarker for Diagnosis and Monitoring Patients With Prostate Carcinoma." <i>Prostate</i> , 23:201-212, 1993.
	C21	Ikonen <i>et al.</i> , "Prohibitin, an antiproliferative protein, is localized to mitochondria," <i>FEBS Letters</i> , 358(3):273-277, 1995.
	C22	Ino <i>et al.</i> , "Expression of aminopeptidase A in human gestational choriocarcinoma cell lines and tissues," <i>Placenta</i> , 21:63-72, 2000.
	C23	Koivunen <i>et al.</i> , "Inhibition of Beta(2) Integrin-mediated Leukocyte Cell Adhesion by Leucine-Leucine-Glycine Motif-containing Peptides." <i>J. Cell Biol.</i> , 153:905-915, 2001.
	C24	Koivunen <i>et al.</i> , "Tumor targeting with a selective gelatinase inhibitor," <i>Nature Biotechnol.</i> , 17:768-774, 1999a.
	C25	Larocca <i>et al.</i> , "Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage," <i>FASEB J.</i> , 13:727-734, 1999.
	C26	Mahboubi <i>et al.</i> , "IL-11 Activates Human Endothelial Cells to Resist Immune-Mediated Injury," <i>J. Immunol.</i> , 164:3837-3846, 2000.
	C27	Melnick and Argon, "Molecular chaperones and the biosynthesis of antigen receptors." <i>Immunol. Today</i> , 16:243-250, 1995.
	C28	Misra <i>et al.</i> , "The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction," <i>J Biol Chem.</i> , 277(44):42082-7, 2002.
	C29	Murphy <i>et al.</i> , "Evaluation and Comparison of Two New Prostate Carcinoma Markers. Free-Prostate Specific Antigen and Prostate Specific Membrane Antigen." <i>Cancer</i> , 78:809-818, 1996.
	C30	O'Dowd <i>et al.</i> , "Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer," <i>J. Urol.</i> , 158:687-698, 1997.
	C31	Pasqualini and Ruoslahti, "Organ targeting <i>in vivo</i> using phage display peptide libraries," <i>Nature</i> 380:364-366, 1996.

25716066.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C32	Pasqualini <i>et al.</i> , "Aminopeptidase N I a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis," <i>Cancer Res.</i> , 60:722-727, 2000.
	C33	Pasqualini, "Vascular targeting with phage peptide libraries," <i>The Quart. J. Nucl. Med.</i> , 43:159-162, 1999.
	C34	Piironen <i>et al.</i> , "Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum." <i>Clin. Chem.</i> , 42:1034-1041, 1996.
	C35	Poul and Marks, "Targeted Gene Delivery to Mammalian Cells by Filamentous Bacteriophage," <i>J. Mol. Biol.</i> , 288:203-211, 1999.
	C36	Raisler <i>et al.</i> , "Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringle 1-3 of angiostatin reduce retinal neovascularization," <i>Proc. Natl. Acad. Sci.</i> , 99:8909-8914, 2002.
	C37	Rajotte and Ruoslahti, "Membrane Dipeptidase Is the Receptor for a Lung-targeting Peptide Identified by <i>in Vivo</i> Phage Display," <i>J Biol Chem.</i> , 274:11593-11598, 1999.
	C38	Rajotte <i>et al.</i> , "Molecular Heterogeneity of the Vascular Endothelium Revealed by In Vivo Phage Display," <i>J Clin. Invest.</i> , 102:430-437, 1998.
	C39	Ruoslahti, "RGD And Other Recognition Sequences For Integrins," <i>Annu. Rev. Cell Dev. Biol.</i> , 12:697-715, 1996.
	C40	Shi <i>et al.</i> , "Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo," <i>Cancer Gene Therapy</i> , 9:513-521 (2002)
	C41	Smith and Scott, "Libraries of Peptides and Proteins Displayed on Filamentous Phage," <i>Meth. Enzymol.</i> , 217:228-257, 1993.
	C42	Trepel <i>et al.</i> , "Molecular Adaptors for Vascular-Targeted Adenoviral Gene Delivery," <i>Hum. Gene. Ther.</i> , 11:1971-1981, 2000.
	C43	Tsimanis <i>et al.</i> , "Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia," <i>Leuk. Lymphoma</i> , 42(1-2):195-205, 2001.
	C44	Veltri <i>et al.</i> , "Interleukin-8 Serum Levels in Patients With Benign Prostatic Hyperplasia and Prostate Cancer," <i>Urology</i> , 53:139-147, 1999.

25716066.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C45	Vendruscolo <i>et al.</i> , "Three key residues form a critical contact network in a protein folding transition state," <i>Nature</i> , 409:641-45, 2001.
	C46	Wang <i>et al.</i> , "Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function," <i>Oncogene</i> , 18(23):3501-3510, 1999.
	C47	Weitzman <i>et al.</i> , "Adenovirus Vectors in Cancer Gene Therapy," <i>In: Gene Therapy Technology and Vector Systems</i> , 2:17-25, 1997.
	C48	Wickham, "Targeting adenovirus," <i>Gene Ther</i> , 7:110-114, 2000.
	C49	Zhang, "Development and application of adenoviral vectors for gene therapy of cancer," <i>Cancer Gene Ther.</i> , 6:113-138, 1999.

25716066.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.